3 Houston startups announce strategic appointments across health tech, materials, and software

short stories

Here are three of the latest updates on new execs and advisory appointments from Houston startups. Photo via Getty Images

Three Houston tech startups have new hires they're excited about this summer. From new board members to c-level execs, here's who's moving and shaking in Houston innovation.

Former Memorial Hermann CEO joins board of ZIBRIO

This Houston medical device startup has added a big name to its board. Photo courtesy of ZIBRIO

Dan Wolterman, who served as president and CEO of Memorial Hermann Health System for 15 years, has been named to the board of directors of Houston-based ZIBRIO. The health tech company, which was founded based on NASA technology, has developed a device that measures balance.

"We're delighted to have Dan on the team," says Katharine Forth, ZIBRIO CEO and co-founder, in a news release. "He understands ZIBRIO's vision to work across the full continuum of care, empowering older patients and clinicians with quantifiable fall prevention. His experience and enthusiasm will be invaluable in helping us to achieve it."

Falling is the top cause of trauma injury and trauma death across all age groups, according to ZIBRIO's release, and the current cost of falls in people over 65 is $50 billion – which is expected to double.

"ZIBRIO is coming to market at a time when population health and prevention are key for Healthcare systems to generate outcomes. They have a strong team and an elegant solution to a complex problem that will help millions," Wolterman says in the release.

Inhance adds to its C-suite

Inhance Technologies has added an integral member to its leadership. Photo via inhancetechnologies.com

Inhance Technologies, an international provider of polymer material science solutions based in Houston, has named its new CFO. Andrew Leeser, previously at Cimarron Energy, has joined the company to lead global finance, accounting and treasury functions, as well as human resources and information technology.

"I'm delighted to welcome Andrew to the Inhance Technologies family. He has an excellent track record in organizations spanning a range of industries, and I'm sure that his experience will help us continue on our upward trajectory," says Andrew Thompson, president and CEO of Inhance Technologies, in a news release. "We look forward to working with him to build a bright future for the company and our customers as we help them make a conscious choice towards more sustainable plastics."

The company just recently announced its expansion, including another new C-level exec and a new 75,000-square-foot site in St. Louis.

"I'm very pleased to have joined Inhance Technologies and I look forward to helping the organization achieve its goals over the next few years. With the significant growth in demand for our fully recyclable barrier technology Enkaseä, as well as our global expansion, there is no doubt I'm joining the company at an exciting time," says Leeser in the release.

Houston fintech unicorn names new council

Meet the new council dedicated to supporting HighRadius's new platform. Photo via LinkedIn

HighRadius, a Houston-based fintech company that reached unicorn status last year, has announced the members of its advisory council for its new microlearning and community platform Highako Academy.

Bob Shultz, managing partner of Quote-to-Cash Consulting, will serve as chairman of the council.

Other council members include:

  • John LaRocca, Sr. Director of Global Credit, Hitachi Vantara
  • Roger Torneden, Director of Business, Management and Legal Programs for UCLA Extension
  • R. Britt Hastey, Chair, Business Administration Department, Los Angeles City College
  • Bruce Lynn, Managing Partner, the FENG LLC
  • Scott Blakeley, Partner, Blakeley LLP

The council "will identify and improve courseware, certification programs and the methods of delivery based on current and future industry and professional trends," according to an email from the company. Highako Academy is aimed at helping teams and customers develop critical industry skills.

"Our customers have asked us for an online self-service learning platform, and that led us to launch highako.com as a beta platform last year," says Urvish Vashi of HighRadius in a recent release. "With 10,000+ users on the platform and a vibrant partner ecosystem consisting of credit groups, collection agencies, attorneys and industry associations, we see this echoing a larger trend of millennials and Gen Z gravitating towards microlearning platforms."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings